Carbohydrate antigen 19-9 - tumor marker: Past, present, and future.
Carbohydrate antigen 19-9 - tumor marker: Past, present, and future.
复制标题
DOI：
10.4240/wjgs.v12.i12.468
复制
发表时间：
2020-12-27
影响因子：
2
通讯作者：
Shelat VG
中科院分区：
文献类型：
--
作者：
Lee T;Teng TZJ;Shelat VG
碳水化合物抗原 19-9 (CA 19-9) 是一种细胞表面糖蛋白复合物，最常与胰腺导管腺癌 (PDAC) 相关。 Koprowski 于 1979 年首次在结直肠癌细胞系中使用小鼠单克隆抗体进行了描述。从历史上看，它是诊断、管理和预测 PDAC 最常用的肿瘤标志物之一。此外，CA 19-9 水平升高可作为可疑良性胰腺疾病手术的指征。 CA 19-9 在胆道中的另一个常见应用包括其用作诊断胆管癌的辅助手段。然而，其临床价值并不局限于肝胰胆系统。现实情况是，不断发展的文献拓宽了 CA 19-9 的临床价值。 CA 19-9 在患者检查中的潜在价值将其范围扩展到胃肠道癌症（例如结直肠癌和食道癌），并进一步超出胃肠道范围，包括泌尿科、妇科、肺部和甲状腺病理。除了在研究中的作用外，CA 19-9 还成为 PDAC 和急性胰腺炎的潜在治疗靶点。为了巩固其广泛的效用，我们评估和审查了生物标志物当前的效用以及在研究和管理中的局限性，同时讨论了 CA 19-9 在未来工作中的潜在应用。
Carbohydrate antigen 19-9 (CA 19-9) is a cell surface glycoprotein complex most commonly associated with pancreatic ductal adenocarcinoma (PDAC). Koprowski first described it in 1979 using a mouse monoclonal antibody in a colorectal carcinoma cell line. Historically, it is one of the most commonly used tumor markers for diagnosing, managing, and prognosticating PDAC. Additionally, elevated CA 19-9 levels are used as an indication for surgery in suspected benign pancreatic conditions. Another common application of CA 19-9 in the biliary tract includes its use as an adjunct in diagnosing cholangiocarcinoma. However, its clinical value is not limited to the hepatopancreatobiliary system. The reality is that the advancing literature has broadened the clinical value of CA 19-9. The potential value of CA 19-9 in patients' workup extends its reach to gastrointestinal cancers – such as colorectal and oesophageal cancer – and further beyond the gastrointestinal tract - including urological, gynecological, pulmonary, and thyroid pathologies. Apart from its role in investigations, CA 19-9 presents a potential therapeutic target in PDAC and acute pancreatitis. In a bid to consolidate its broad utility, we appraised and reviewed the biomarker’s current utility and limitations in investigations and management, while discussing the potential applications for CA 19-9 in the works for the future.
影响因子：
3.4
作者：
Lee JW;Kim YT;Lee SH;Son JH;Kang JW;Ryu JK;Jang DK;Paik WH;Lee BS
通讯作者：
Lee BS